Shots: Singlomics to receive upfront and is eligible to receive regulatory & commercial milestones along with royalties on sales of products. BeiGene get an exclusive global right (Ex-China) to develop & commercialize its preclinical assets (DXP-593 and DXP-604), as well as for a series of Ab sequences targeting COVID-19 The companies plan to initiate P-I […]Read More
Shots: AstraZeneca has licensed Vanderbilt University’s coronavirus-neutralizing Abs & plans to advance a pair of these mAbs into clinical development as a combination therapy for COVID-19. The agreement follows AstraZeneca and Vanderbilt collaboration in Apr’20 AstraZeneca has evaluated the ability of 1,500+ mAbs to bind to the SARS-CoV-2 virus and inhibit its capacity to infect […]Read More
Shots: AstraZeneca highlighted its efforts towards the development of Ab against the pandemic SARS-CoV-2 virus by deploying its internal expertise and via news collaboration with government and academia The Chinese Academy of Sciences and Vanderbilt University Medical Center are providing AstraZeneca with genetic sequences for Ab, discovered against SARS2-CoV-2 for further in silico and in […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
